VIJOICE® (alpelisib) FDA Approved for the Treatment of Patients with PIK3CA-Related Overgrowth Spectrum (PROS), Available Exclusively at Biologics by McKesson
Biologics by McKesson became the exclusive specialty pharmacy for VIJOICE, indicated for adults and children age 2 and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum.
OJEMDA (tovorafenib), FDA Approved for Pediatric Low-Grade Glioma, Available at Biologics by McKesson
Biologics by McKesson joined a limited network as a specialty pharmacy provider for OJEMDA, an oral RAF inhibitor for pediatric low-grade glioma.